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Volume 6Available online xxxBackground: Proton-pump-inhibitors (PPIs) are frequently prescribed for the management of anticancer drug-related
gastrointestinal symptoms. Palbociclib is a weak base with pH-dependent solubility and potential drug-drug
interaction at the absorption level may affect clinical pharmacokinetics. The current study was aimed at
investigating the effect of co-administration of PPIs and palbociclib on progression-free survival (PFS) in metastatic
breast cancer (mBC) patients.
Patients and methods: Patients affected by estrogen receptor-positive, human epidermal growth factor receptor 2-
negative mBC, who were candidates for first-line treatment with palbociclib, were enrolled in this retrospective
observational study. Patients were defined as ‘no concomitant PPIs’ if no PPIs were administered during palbociclib
treatment, and as ‘concomitant PPIs’ if the administration of PPIs covered the entire or not less than two-thirds of
treatment with palbociclib. All clinical interventions were made according to clinical practice.
Results: A total of 112 patients were enrolled in the study; 56 belonged to the ‘no concomitant PPIs’ group and 56 to
the ‘concomitant PPIs’ group. Seventy-one patients were endocrine-sensitive and received palbociclib and letrozole, and
43 were endocrine-resistant and were treated with palbociclib and fulvestrant. The most prescribed PPI was
lansoprazole. Patients taking PPIs had a shorter PFS than those taking palbociclib and endocrine therapy alone (14.0
versus 37.9 months, P < 0.0001). Multivariate analysis confirmed concomitant PPIs as the only independent
predictive factor for shorter PFS (P ¼ 0.0002). PFS was significantly longer in estrogen-sensitive mBC with no
concomitant PPIs compared with patients taking PPIs or estrogen-resistant patients, with and without PPIs (P <
0.0001). No correlation with adverse events was found when considering grade >2 hematological toxicities
[Common Terminology Criteria for Adverse Events (CTCAE) scale].
Conclusions: The present study demonstrates that concomitant use of PPIs in mBC patients treated with palbociclib has
a detrimental effect on PFS. Therefore, it is recommended to prescribe PPIs with caution in these patients, strictly
adhering to the indications in the summary of product characteristics (RCP).
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- Issue 5 - 2021although there may be pharmacologic interactions since a
substantial number of targeted drugs exhibit pH-dependent
solubility.1 Therefore, drug-drug interactions (DDI) at the
absorption level should be considered as a possible cause of
treatment failure in cancer patients.2 As a matter of fact,
gastric pH elevation by PPIs was found to significantly
reduce the oral bioavailability of many anticancer drugs,
particularly those with exponentially decreasing solubility in
the pH range 1-4.3,4 Whether or not these changes may be
clinically relevant depends on the type of anticancer drug
involved.5 Prolonged acid suppression by PPIs in cancer
patients was found to reduce the antitumor efficacy ofhttps://doi.org/10.1016/j.esmoop.2021.100231 1
ESMO Open M. Del Re et al.capecitabine6,7 and pazopanib,8 whereas it did not seem to
influence clinical outcomes in patients treated with
epidermal growth factor receptor (EGFR) inhibitors.9-11
Palbociclib is an oral cyclin-dependent kinase 4 and 6
(CDK4/6) inhibitor able to suppress DNA synthesis by
inhibiting the progression of cells from G1 to S phase.12
Palbociclib demonstrated clinical efficacy in combination
with fulvestrant or aromatase inhibitors as first- or second-
line treatment of premenopausal and postmenopausal,
hormone receptor-positive, human epidermal growth factor
receptor 2 (HER2)-negative metastatic breast cancer (mBC)
patients.13,14 Palbociclib is a weak base with pH-dependent
solubility that rapidly decreases to values <0.5 mg/ml as pH
increases above 4.5 (i.e. gastric pH typically achieved by
PPIs). Coadministration of multiple doses of rabeprazole
was found to reduce palbociclib mean area under the
concentration-time curve (AUC) and maximum plasma
concentration (Cmax) by 62% and 80%, and 13% and 41%
under fasting and fed conditions, respectively.15
Studies on ribociclib examining solubility, physiologically-
based pharmacokinetic modeling, clinical trial data, and
population pharmacokinetics suggest that drug absorption
is unlikely to be affected by changes in gastric pH that occur
following food intake or concomitant use of PPIs.16,17 To our
knowledge, no data are available on DDIs between abe-
maciclib and PPIs or palbociclib and PPIs other than
rabeprazole.
The current study is aimed at investigating the effect of
concomitant PPIs (mainly lansoprazole) on palbociclib
progression-free survival (PFS) in patients treated as first-
line for estrogen-positive, HER2-negative mBC.PATIENTS AND METHODS
Hormone receptor-positive, HER2-negative mBC patients
treated with palbociclib with or without concomitant PPI
treatment were enrolled in this observational study. Hor-
mone receptor-positive, HER2-negative BCs were defined as
tumors with estrogen and/or progesterone receptors
expression >1% and HER2-negative (score 0 or 1þ or
negative to immuno-histochemistry). Patients were defined
as ‘no concomitant PPIs’ if no PPIs were administered
during palbociclib treatment, while ‘concomitant PPIs’ was
used to indicate that the administration of PPIs covered the
entire or not less than two-thirds of treatment with pal-
bociclib. According to the duration of previous endocrine
response, each patient was classified as endocrine-sensitive
(if relapsed at least 12 months after the completion of
adjuvant endocrine therapy or with de novo advanced
breast cancer) or endocrine-resistant (if relapsed on or
within 12 months after ending adjuvant endocrine
therapy).18
All pharmacological and clinical interventions were made
according to clinical practice. In particular, palbociclib was
administered at a dose of 125 mg orally, once daily for 21
consecutive days, followed by 7 days off, to comprise a
complete cycle of 28 days plus fulvestrant or letrozole,
according to clinical practice. Palbociclib reduction to 100 or2 https://doi.org/10.1016/j.esmoop.2021.10023175 mg was made according to the toxicity profile. Patients
were advised to take the dose of lansoprazole (15 mg),
esomeprazole (20 mg), omeprazole (10 mg), or pan-
toprazole (20 mg) in the morning at breakfast. Palbociclib
was taken at lunchtime and patients were advised not to
take strong inhibitors or inducers of cytochrome P450 3A4
(CYP3A4). The prescribing physician monitored the patient’s
compliance with the recommendations. Toxicity was graded
according to Common Terminology Criteria for Adverse
Events (CTCAE v5). The study was approved by the local
Ethics Committee and conducted in accordance with the
Helsinki Declaration. All patients released a written
informed consent.Statistical analysis
Categorical variables including Eastern Cooperative
Oncology Group (ECOG) performance status, lines of
treatment, hormone sensitivity, premenopausal versus
postmenopausal status, visceral versus bone disease,
and number of tumor sites were described by absolute and
relative frequencies and quantitative factors by median and
range. PFS was defined as the time from treatment start to
progression of disease. The KaplaneMeier method was
used to create survival curves and the log-rank test was
used to evaluate the differences between curves. The Cox
hazard regression method was used to identify independent
risk factors for PFS. Differences were considered significant
at P < 0.05. All statistical analyses were carried out with
MedCalc Statistical Software version 14.8.1 (MedCalc Soft-
ware, bvba, Ostend, Belgium).
RESULTS
A total of 112 patients were enrolled in the study, 56 of
whom did not receive any PPI during palbociclib treatment
and 56 received concomitant palbociclib-PPI treatment; 71
patients were endocrine-sensitive and were administered a
combination of palbociclib and letrozole, and 41 were
defined as endocrine-resistant and were treated with the
combination of palbociclib and fulvestrant. The majority of
patients received palbociclib at a dose of 125 mg (61.6%),
26.8% reduced the dose to 100 mg, and 9.8% of patients
needed the 75 mg dose. No statistically significant differ-
ences were found comparing the ‘no concomitant PPIs’
versus ‘concomitant PPIs’ based on their clinical character-
istics. Clinical characteristics of patients and the type of PPI
used are reported in Table 1.
The overall population was stratified according to PFS
and the use of concomitant PPIs, showing that patients
taking PPIs had a shorter PFS with respect to patients taking
palbociclib and endocrine therapy alone (14.0 versus 37.9
months, P < 0.0001; Figure 1). The univariate analysis
included age, number of metastatic sites at palbociclib
baseline, endocrine sensitivity or resistance, ECOG, meno-
pausal status, visceral disease, and palbociclib dose reduc-
tion. Age, ECOG, and endocrine sensitivity or resistance
were significantly associated to PFS (P ¼ 0.04,
P ¼ 0.02 and P ¼ 0.001, respectively; Table 2). TheVolume 6 - Issue 5 - 2021
Table 1. Clinical characteristics of patients and their distribution across PPI groups
Total number of patients
(n [ 112)





Age at the diagnosis of metastasis (years), median (range) 63 (35-86) 61.5 63 d
Pre/postmenopause, n (%) 0.61
Premenopause 19 (16.96) 11 (19.6) 8 (14.3)
Postmenopause 93 (83.04) 45 (80.4) 48 (85.7)
ECOG PS, n (%) 0.64
0 84 (75) 44 (78.6) 40 (71.4)
1 25 (22.3) 11(19.6) 14 (25)
2 3 (2.7) 1 (1.8) 2 (3.6)
Disease site, n (%) 0.26
Visceral 55 (49.1) 31 (55.4) 24 (42.9)
Non-visceral 57 (50.9) 25 (44.6) 32 (57.1)
Type of HT associated to palbociclib, n (%) 1
Fulvestrant 39 (34.8) 20 (35.7) 19 (33.9)
Letrozole 73 (65.2) 36 (64.3) 37 (66.1)
Endocrine-sensitive or -resistant disease, n (%) 1
Sensitive 71 (63.4) 35 (62.5) 36 (64.3)
Resistant 41(36.6) 21 (37.5) 20 (35.7)
Dose reduction of palbociclib, n (%) 0.21
125 mg 69 (61.6) 36 (64.3) 33 (58.9)
100 mg 30 (26.8) 11 (19.6) 19 (33.9)
75 mg 11 (9.8) 8 (14.3) 3 (5.4)
Unknown 2 (1.8) 1 (1.8) 1 (1.8)





ECOG PS, Eastern Cooperative Oncology Group (ECOG) performance status; HT, hormone therapy; PPIs, proton pump inhibitors.
M. Del Re et al. ESMO Openmultivariate analysis confirmed the use of concomitant PPIs
as the only independent predictive biomarker for shorter
PFS (hazard ratio 2.77; 95% confidence interval: 1.62-4.75;
P ¼ 0.0002; Table 2). To evaluate the effective role of PPIs
over endocrine sensitivity in PFS analysis, patients were
stratified into four groups: (i) endocrine-sensitive patients
and no concomitant PPIs, (ii) endocrine-sensitive patients
and concomitant PPIs, (iii) endocrine-resistant patients and
no concomitant PPIs, and (iv) endocrine-resistant patients
and concomitant PPIs. PFS was significantly longer in
endocrine-sensitive patients with no concomitant PPIs
compared with the other three groups (P < 0.0001;
Figure 2). The worse PFS was identified in the group of
endocrine-resistant patients with concomitant use of PPIs
(6.3 months; Figure 2). No correlation with adverse events
was found considering grade >2 hematological toxicities,
since neutropenia, anemia, and thrombocytopenia were
equally distributed across the two groups of patients and
the majority of patients developed toxicity during the first
and/or second cycle of therapy (P ¼ 0.8).
DISCUSSION
It has been recognized that among different factors that can
influence drug absorption, pH solubility is the most relevant
one.19 In particular, an increase in gastric pH was found to
affect the anticancer activity of weakly basic drugs by
reducing their bioavailability.3,20 To our knowledge, this is
the first study demonstrating that the use of PPIs in mBC
patients treated with palbociclib has a detrimental effect onVolume 6 - Issue 5 - 2021PFS. Regarding the mechanism underlying the unfavorable
impact of PPIs on PFS, it is conceivable that the increase in
gastric pH may have lowered palbociclib plasma concen-
trations affecting treatment efficacy. Indeed, palbociclib is a
weak base with pH-dependent solubility that rapidly de-
creases as pH increases above 4.5. The changes induced on
palbociclib pharmacokinetics by rabeprazole in fed condi-
tion were considered not clinically relevant,15 and no re-
striction for the concomitant use of PPIs are reported in the
palbociclib label.21 At variance with the current study,
however, Sun and co-workers15 did not evaluate the effect
of rabeprazole on clinical outcomes. Furthermore, the
impact on palbociclib pharmacokinetics by rabeprazole
given for 6 days only may have been underestimated, since
short-term treatment with PPIs does not elevate the
intragastric pH over the whole 24-h range.14,22 In the cur-
rent study, PPIs (mainly lansoprazole) were given for the
entire or not less than two-thirds of palbociclib treatment, a
treatment schedule that most likely induces a larger and
more constant elevation of intragastric pH.
Although the absolute threshold level below which the
activity of palbociclib may be affected is currently unknown,
it has been reported that the free average steady-state
concentration (Css) for palbociclib was similar to the
in vitro cell potency (IC50), with a Css/IC50 ratio of 0.94.
23
Findings of the current study support the hypothesis that
long-term treatment with PPIs may reduce palbociclib
plasma levels below the minimum effective concentration,
thus affecting its efficacy to some degree. A limitation ofhttps://doi.org/10.1016/j.esmoop.2021.100231 3

























Figure 1. Overall population treated with palbociclib plus endocrine therapy stratified according to progression-free survival and the use of concomitant PPIs.
ET, endocrine therapy; PPIs, proton pump inhibitors.
Table 2. Univariate and multivariate analysis for progression-free survival
Variables Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Age (years) 1.68 (1.01-2.78) 0.04 1.46 (0.86-2.47) 0.15
Number of metastatic sites 1.09 (0.85-1.42) 0.48
Endocrine-sensitive or -resistant disease 2.29 (1.38-3.78) 0.001 1.83 (0.93-3.58) 0.08
ECOG PS 1.82 (1.07-3.11) 0.02 1.64 (0.94-2.86) 0.07
Pre/postmenopause 1.92 (0.87-4.21) 0.10
Visceral or non-visceral disease 1.46 (0.88-2.40) 0.14
Dose reduction 0.91 (0.55-1.52) 0.73
Concomitant use of PPIs 2.93 (1.71-5.03) 0.0001 2.77 (1.62-4.75) 0.0002
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group (ECOG) performance status; PPIs, proton pump inhibitors; HR, hazard ratio. Statistically significant values
are reported in bold.
ESMO Open M. Del Re et al.our study is the lack of assessment of changes in palbociclib
pharmacokinetics induced by PPIs. It has been reported,
however, that short-term treatment with rabeprazole re-
duces palbociclib Cmax by 80% and 41% under fasting and
fed conditions, respectively.15
Several lines of evidence suggest no impact of gastric pH-
altering agents on the absorption of ribociclib.16,17 Samant
et al.16 analyzed steady-state pharmacokinetic parameters
of ribociclib (600 mg) during PPI use and found no differ-
ences in AUC and Cmax between the two groups. The
different behavior of ribociclib and palbociclib in the acid
microenvironment may be due to different dissolution
properties. Indeed, ribociclib solubility is >2.4 mg/ml at pH
4.5,16 whereas that of palbociclib is >0.5 mg/ml only at pH
<4.5.15 In the non-compartmental analysis of clinical data,
Samant et al.16 found that trough concentration (Ctrough)4 https://doi.org/10.1016/j.esmoop.2021.100231mean values of ribociclib were 597 and 711 ng/ml in pa-
tients taking or not taking PPIs, respectively. Such a
reduction in the ribociclib Ctrough is unlikely, however, to be
clinically relevant due to its wide therapeutic index char-
acterized by an average free Css that largely exceeds the
in vitro cell potency (Css/IC50 ratio >25).
23 Concerning
abemaciclib, the drug shows similarities in pharmacoki-
netics compared with the other CDK4/6 inhibitors. Perhaps
a feature that is worth mentioning is the saturable ab-
sorption which justifies, together with the shorter half-life
and the smaller volume of distribution compared with
ribociclib and palbociclib, a continuous, twice-daily
administration.24
Another interesting question is whether P-glycoprotein
(P-gp) inhibition may have influenced the effects of PPIs on
PFS observed in the current study. Indeed, PPIs are knownVolume 6 - Issue 5 - 2021
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Figure 2. Effect of concomitant PPIs on progression-free survival over endocrine sensitivity.
Patients were stratified in four groups: (1) endocrine-sensitive patients and no concomitant PPIs, (2) endocrine-sensitive patients and concomitant PPIs, (3) endocrine-
resistant patients and no concomitant PPIs, and (4) endocrine-resistant patients and concomitant PPIs.
ET, endocrine therapy; PPIs, proton pump inhibitors.
M. Del Re et al. ESMO Opento be moderate inhibitors of P-gp25 and palbociclib is a P-gp
substrate.26 Furthermore, pantoprazole was found to alter
tyrosine kinase inhibitor (TKI) pharmacokinetics by affecting
breast cancer resistance protein (BCRP) and P-gp.22 If P-gp
inhibition by PPIs had been the main mechanism of DDI
observed in our study, it would have produced an opposite
effect to that induced by the increase in gastric pH (i.e.
higher palbociclib exposure with evidence of toxicity). This
hypothesis does not agree with our data since no statistical
differences in the incidence of adverse drug reactions were
observed in the presence or absence of PPIs. Accordingly,
although rabeprazole was found to inhibit P-gp activity at
clinically relevant concentrations, the net effect was the
reduction of palbociclib exposure.15 Therefore, changes in
gastric pH caused by PPIs appear to be the main mechanism
of interaction with drugs that require an acid microenvi-
ronment for dissolution and absorption.27
Other examples of DDIs among PPIs and TKIs (i.e. pazo-
panib, sunitinib, gefitinib, and erlotinib) have been re-
ported.9,28-33 A meta-analysis on 16 retrospective studies
for a total of 372 418 patients with gastrointestinal, renal,
and non-small-cell lung cancers, soft tissue sarcomas, or
solid tumors of mixed histology, showed a significant impact
of PPI treatment on survival outcomes in patients receiving
oral anticancer drugs.34 Another retrospective study on
12 538 patients with lung, renal, liver, pancreatic cancer,
and chronic myelogenous leukemia evaluated the impact of
concomitant PPI administration on overall survival and
treatment discontinuation 90 days and 1 year after the end
of the exposure. This work retrospectively demonstrated
that the use of PPIs was associated with an increased risk of
death in TKI-treated patients.35
The main limitation of this study is the retrospective
nature. However, our data suggest caution in the long-termVolume 6 - Issue 5 - 2021use of PPIs in this specific population and a careful
assessment of benefits and risk of coadministration of
strong acid-reducing agents with anticancer drugs whose
solubility is dependent on the pH at the site of absorption.
The choice of PPI should also be carefully evaluated. For
example, rabeprazole can maintain longer acid suppression
than other drugs of the same class; the administration of
H2-antagonists instead of PPIs should also be considered.
Although increasing the dose of palbociclib in patients using
PPIs may be theoretically logical, it is probably not an
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